Skip to content

Advertisement

Featured article: Pharmacological inhibition of EZH2 disrupts the female germline epigenome

Recently discovered drugs that target epigenetic modifying complexes are providing new treatment options for a range of cancers that affect patients of reproductive age. Although these drugs provide new therapies, it is likely that they will also affect epigenetic programming in sperm and oocytes and ultimately, the offspring of the therapy recipient. 

Call for Papers: Pollution and Epigenetics

Guest Editors: Wim Vanden Berghe (University of Antwerp in Belgium, Lifestyle Epigenetics Editor) and Steven Gray (St James University in Ireland, Nutritional Epigenetics Editor)

 In 2013, it was reported that an eight-year-old girl developed lung cancer [Kessler, R. (2014) Nature. 509(7502):S62-3.]. The cause of her cancer was attributed by her doctor to be due to accumulation of fine particulate matter in her lungs leading to neoplastic change. From diesel particulates to endocrine disruptors, asbestos, heavy metals to molecules like bisphenol A (BPA), it is becoming increasingly clear that man’s propensity to pollute has significant consequences on human health. Moreover, strong evidence now links such pollution to changes within our epigenomes. In this thematic series, we explore the causes and consequences of pollution on the epigenome, how this may have effects not only on the epigenetics of the individual exposed to such pollution, but also review how this may be further exacerbated by downstream or “transgenerational” inheritance of these epigenetic changes. With the recent world-wide concerns regarding “micro-plastics”, should we be concerned that nano-technology could further expose our epigenomes to additional environmental challenges?

In a series of cutting-edge reviews Clinical Epigenetics will explore these possibilities in a thematic series on “Pollution and Epigenetics,” reviewing the critical roles that exposure to environmental pollution may have on the epigenome.

Articles

Most accessed articles RSS

View all articles

2016

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

2015

Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015

 

Aims & Scope

Clinical Epigenetics is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome. The journal is divided into the following sections:

  • Aging, development, imprinting and reproductive epigenetics
  • Allergy, immunology, pathogens and inflammation
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic disease
  • Epigenetic therapy and clinical trials
  • Innovative epigenetics therapies
  • Neurology and psychiatry
  • Nutritional and environmental epigenetics
  • All other subjects

For more information on the the section aims and scope visit our sections information page.

Upcoming Meetings

Systems Epigenetics: Towards Precision Medicine Cancer Conference

November 27-30, 2018 in Amsterdam, The Netherlands at the KIT Royal Tropical Institute

Learn more about the meeting here

8th Clinical Epigenetics International Meeting

March 7-8, 2019 - Düsseldorf, Germany


Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Meet our Editors-in-Chief

Lucia AltucciLucia Altucci studied Medicine & Surgery at Federico II University of Naples, Italy. After obtaining a Specialization degree in Medical Oncology and a PhD degree in molecular and cellular Pathology, she worked as Assistant and later as Associate Professor at the Second University of Naples, Italy. She has been Post-Doc scientist both at the Imperial Cancer Research Fund (ICRF) in London, UK and at the ‘Institut de Génétique et de Biologie Moléculaire et Cellulaire’ (IGBMC) in Strasbourg, France. She is currently Professor of General Pathology and Rector’s delegate for Research & Innovation at University of Campania ‘Luigi Vanvitelli’ in Naples, Italy.

Lucia’s research interests are in: translational medicine (particularly on genome and epigenome deregulation in cancer), stemness, differentiation, cell death processes, and the application of epigenome-based drug discovery approaches in human diseases. As a co-Editor-in-Chief, she is committed to improve the standards of Clinical Epigenetics and to further expand basic and applied epigenetics research at a preclinical and clinical level. Given her medical expertise, she will focus on improving integration of ‘basic’ epigenome knowledge as possible disease-related markers as well as on the potential of chromatin modulation as innovative treatments against human pathologies or as a preventive strategy in predisposed patients.


Marianne Rots © © Worcflow - Visuele marketing & BeeldcommunicatieMarianne Rots studied Medical Biology at the University of Amsterdam, the Netherlands. After obtaining a PhD degree in Medical Oncology in 2000 at the VU Medical Center Amsterdam, she has been a postdoctoral scientist at the Gene Therapy Center of the University of Alabama in Birmingham, AL, USA. In 2001, she was recruited as an Assistant Professor to co-establish the Department of Therapeutic Gene Modulation, School of Pharmacy at the University of Groningen, NL. Appointed as an Associate Professor in 2007, she joined the Department of Pathology and Medical Biology, University Medical Center Groningen, the Netherlands where she currently is Full Professor of Molecular Epigenetics.

Marianne also serves as a vice-chair of the EU H2020 COST Action CM1406 (www.EpiChemBio.eu) and chairs the Program Committee of the Master BioMedical Sciences and Medical Pharmaceutical Sciences at the Faculty of Science and Engineering, University of Groningen. She pioneered epigenetic editing approaches to rewrite epigenetic marks at a given genomic location, allowing to functionally validate epigenetic mutations and to translate these into precision therapeutic targets: “towards the curable epigenome”. As a chief editor, she is committed to maintain the high standards of Clinical Epigenetics and to further expand on the impact of this platform. Her aim is to continue to inform the scientific community on the clinical relevance of epigenetic dysregulations through publishing state of the art research manuscripts. Through the commissioning of reviews or letters to the editors, the communication between clinicians and biologists/chemists is encouraged, while exciting hypotheses can be put forward to stimulate scientific innovation.
(Photo credit: © Worcflow - Visuele marketing & Beeldcommunicatie)

Society Information

The "Clinical Epigenetics Society" (CLEPSO) is a non-profit organization founded at Saarland University.

The society has five main objectives:

  • Promotion and support of scientific research projects and initiatives within the field of clinical epigenetics.
  • Promotion of the scientific exchange amongst its members.
  • Encouragement and support of relations to national and international societies within the area of clinical and translational research.
  • Development of an international research and scientific network within the field of clinical epigenetics.
  • Providing a forum for encouraging discussions and contributions to the advancement of clinical epigenetics, through the Clinical Epigenetics journal, Blogs, scientific symposia, meetings, and newsletters.

Advertisement

2016 Journal Metrics

Advertisement